CNS disorder therapeutic - NeuShen Therapeutics/Hangzhou HealZen Therapeutics
Latest Information Update: 23 Jun 2023
At a glance
- Originator Hangzhou HealZen Therapeutics
- Developer Hangzhou HealZen Therapeutics; NeuShen Therapeutics
- Class Small molecules
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical CNS disorders